Stem Cell News, page-499

First 499 Last

Share
Profile

Follow
bedger

7,844 Posts.

7086

07/02/24

16:54

Post #: 72288809
Share

Originally posted by atomikrej: ↑

It was $1.80 right after an indicative takeover offer by Sumitomo happened.
This was late 2019. The offer eventually fell through and the share dropped a bit.
Soon after Covid hit and apparently this had a big negative impact on small bios. With Cynata, recruitment in trials was basically stopped for a year or two. They had a Covid ards trial which didn’t recruit very well and recruitment never finished. We were never told the results of it.
At end of 2021 (from memory) Fujifilm decided to discontinue the GVHD program and give rights back to Cynata. Cynata is now running the P2 trial and just starting to open all the recruitment centres. We are waiting for first patient to be recruited.
in the last few years numerous capital raises were made at lower and lower prices which steadily dropped the share price.
I also don’t think management did much to excite the market. In mid 2023 the previous CEO resigned as well as another director.
While the above sounds bleak, I think we are due for a climb. Probably the most anticipated announcement is the internim analysis of the DFU (diabetic foot ulcer) trial with the first 16 patients. Initial results of first 6 wounds show Cynata’s cells have a big improvement of wound healing over the standard of care. So we’re hoping that is replicated on the 16 patients.
Also recently the recruitment of the OA phase 3 trial was completed. 330 patients were treated in total so about 165 received Cynata’s stem cells to hopefully improve their knee osteoarthritis. That should be big news by any measure, but somehow we’re sitting at $20 mil market cap. Go figure

Expand

...and ironically Mexico's medical industry is seeing a mass influx of "stem cell tourism" as sports/media influencers on social media encourage a swath of US sports stars, in UFC and surfing particularly, to head to Mexico for untrialled stem cell treatments

Whilst listed companies like CYP struggle for decades to get product to market amidst onerous and expensive, but proper, regulatory pathways, private medical companies in Mexico and the like, rake in big dollars from poorly regulated and untrialled treatments:

https://theconversation.com/stem-cell-therapies-why-theyre-expensive-unproven-and-often-dangerous-206548

https://www.medpagetoday.com/special-reports/features/105448

For every sport star influencer like big wave surfer Shane Dorian featured as a success in some crappy publication with no morals:

https://www.surfer.com/trending-news/surfer-shane-dorian-stem-cell

There will be some sad tale you don't hear about quite so readily (his mate dying at the same "institute"):

https://beachgrit.com/2023/10/shane-dorian-medical-tragedy/

These guys literally have been featured in a host of publications that wouldn't know a DFU from a DUI:

https://cellularperformanceinstitute.com/

Whilst CYP's bona-fide phase III Sydney Uni trial struggled for years for recruitment.

CYP Price at posting: 14.5¢ Sentiment: Buy Disclosure: Held
7 Upvote

1 Great analysis

Reply

Top Stories

MIN

Movers and Shakers: Zip Co, MinRes, Kuniko, more – The week's top ASX gainers

Making money: How many microcaps should be in an investor's portfolio?

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

Bitcoin hits fresh record as instos pile into BTC ETFs – and Trump helps, too

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

SCT

Scout proposes 'merger of equals' with US home security providers Roo Inc

DXB

Dimerix links up with US NEPTUNE network to boost recruitment for FSGS study